Amgen 2011 Annual Report Download - page 183

Download and view the complete annual report

Please find page 183 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 184

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184

Board of Directors Leadership
Amgen Inc. Corporate Offi ce
One Amgen Center Drive
Thousand Oaks, California 91320-1799
805-447-1000
Amgen 2011 Annual Report Summary and SEC Form 10-K
Additional copies of the Company’s Form 10-K for the year ended December 31, 2011, fi led with
the U.S. Securities and Exchange Commission, are available without charge, upon written request to
Investor Relations, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799,
or by calling 800-84-AMGEN, or by accessing the Company’s website at www.amgen.com.
Transfer Agent and Registrar
American Stock Transfer & Trust Company
59 Maiden Lane
New York, New York 10038
Stockholder Inquiries
Inquiries related to stock transfers or lost certifi cates should be directed to
American Stock Transfer & Trust Company, 800-937-5449 or 212-936-5100
(www.amstock.com). General information regarding the Company and recent
news releases can be obtained by calling Amgen’s automated stockholder
information line at 800-84-AMGEN or by accessing the Company’s website
at www.amgen.com.
Independent Registered Public Accounting Firm
Ernst & Young LLP
Los Angeles, California
Annual Meeting
The Annual Meeting will be held on Wednesday, May 23, 2012, at 11 a.m. at
the Four Seasons Hotel Westlake Village, Two Dole Drive, Westlake Village,
California 91362.
Price Range of Common Stock
The Company’s common stock trades on The NASDAQ Global Select Market under the symbol
AMGN. The following table sets forth, for the fi scal periods indicated, the range of high and low
closing sales prices of the common stock as quoted on The NASDAQ Global Select Market for
the years 2011 and 2010.
Stockholder Information
2011 2010
High Low High Low
4th Quarter $64.74 $53.90 $57.96 $52.69
3rd Quarter 58.28 48.27 56.32 50.93
2nd Quarter 61.17 53.08 61.14 50.36
1st Quarter 57.31 50.95 60.09 55.71
David Baltimore
President Emeritus and Robert
Andrews Millikan Professor of Biology,
California Institute of Technology
Frank J. Biondi, Jr.
Senior Managing Director,
WaterView Advisors LLC
Robert A. Bradway
President and
Chief Operating Offi cer,
Amgen Inc.
François de Carbonnel
Former Chairman of the Board
and Director, Thomson S.A.
and Director of Corporations
Vance D. Coffman
Retired Chairman of the Board and CEO,
Lockheed Martin Corporation
Rebecca M. Henderson
John and Natty McArthur
University Professor,
Harvard University
Frank C. Herringer
Chairman and Retired CEO,
Transamerica Corporation
Gilbert S. Omenn
Professor of Internal Medicine,
Human Genetics & Public Health
and Director of the Center for
Computational Medicine and Bioinformatics,
University of Michigan; Former CEO,
University of Michigan Health System
Judith C. Pelham
President Emeritus, Trinity Health
Adm. J. Paul Reason,
USN (Retired)
Former Vice Chairman and President,
Metro Machine Corporation
Leonard D. Schaeffer
Retired Chairman & CEO, WellPoint
Senior Advisor, TPG Capital
Kevin W. Sharer
Chairman of the Board and CEO,
Amgen Inc.
Ronald D. Sugar
Retired Chairman of the Board,
Northrop Grumman Corporation
Madhavan Balachandran
Senior Vice President,
Manufacturing
David W. Beier
Senior Vice President,
Global Government and
Corporate Affairs
Fabrizio Bonanni
Executive Vice President,
Operations
Robert A. Bradway
President and
Chief Operating Offi cer
Willard H. Dere
Senior Vice President
and International Chief
Medical Offi cer
Paul R. Eisenberg
Senior Vice President,
Global Regulatory Affairs
and Safety
Sean E. Harper
Executive Vice President,
Research and Development
Rolf K. Hoffmann
Senior Vice President,
International Commercial
Operations
Anthony C. Hooper
Executive Vice President,
Global Commercial
Operations
Alexander Kamb
Senior Vice President,
Discovery Research
Diana L. McKenzie
Senior Vice President and
Chief Information Offi cer
Brian M. McNamee
Senior Vice President,
Human Resources
Joseph P. Miletich
Senior Vice President,
Research and Development
Joshua J. Ofman
Senior Vice President,
Global Value and Access
Jonathan M. Peacock
Executive Vice President
and Chief Financial Offi cer
Anna S. Richo
Senior Vice President and
Chief Compliance Offi cer
David J. Scott
Senior Vice President,
General Counsel and
Secretary
Michael Severino
Senior Vice President,
Global Development and
Corporate Chief Medical Offi cer
Kevin W. Sharer
Chairman of the Board
and CEO
Martin VanTrieste
Senior Vice President,
Quality
Hotlines: Customer Service 800-28-AMGEN | Investor Materials 800-84-AMGEN | Medical Information 800-77-AMGEN | Amgen Assist™ 800-272-9376
Amgen, Amgen Assist™, Aranesp®
, Breakaway from Cancer ®
, Enbrel®
, EPOGEN®
, E.V.O.L.V.E.™, Mimpara®
, Neulasta®
, NEUPOGEN®
, Nplate®
, Prolia®, Sensipar®
, Vectibix®
, and XGEVA®
are trademarks of Amgen Inc. or its wholly owned subsidiaries.
Design by Saputo Design, Inc.